Evidence map›Paper›PMID 29351056›Full record

ArticleRadiation research2018

Remediation of Radiation-Induced Cognitive Dysfunction through Oral Administration of the Neuroprotective Compound NSI-189.

Barrett D Allen, Munjal M Acharya, Celine Lu, Erich Giedzinski, Nicole N Chmielewski, David Quach, Mike Hefferan, Karl K Johe, Charles L Limoli

Open access · bronzeAbstract read
In one paragraph

Article in Radiation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Effects of radiotherapy on the hippocampus and hippocampal neurogenesis: a systematic review of preclinical studies.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Pooled it
  2. Trial
  3. Mapping Cognitive Oncology: A Decade of Trends and Research Fronts.Medical sciences (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Neuroprotective Effects ofDose-response : a publication of International Hormesis Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Barrett D Allena   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Munjal M Acharyaa   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Celine Lua   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Erich Giedzinskia   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Nicole N Chmielewskia   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
David Quachb   Neuralstem, Inc., Germantown, Maryland 20876.
Mike Hefferanb   Neuralstem, Inc., Germantown, Maryland 20876.
Karl K Joheb   Neuralstem, Inc., Germantown, Maryland 20876.
Charles L Limolia   Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
University of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
Translational strategies for protecting the brain against radio- and chemotherapyR01NS074388 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI LIMOLI, CHARLES · 2011 to 2020
$3.5M
NCATS NIH HHS KL2 TR001416NCATS NIH HHS UL1 TR001414NINDS NIH HHS R01 NS074388
6 · The paper itself

Abstract

Clinical management of primary and secondary central nervous system (CNS) malignancies frequently includes radiotherapy to forestall tumor growth and recurrence after surgical resection. While cranial radiotherapy remains beneficial, adult and pediatric brain tumor survivors suffer from a wide range of debilitating and progressive cognitive deficits. Although this has been recognized as a significant problem for decades, there remains no clinical recourse for the unintended neurocognitive sequelae associated with these types of cancer treatments. In previous work, multiple mechanisms have been identified that contribute to radiation-induced cognitive dysfunction, including the inhibition of neurogenesis caused by the depletion of radiosensitive populations of stem and progenitor cells in the hippocampus. To explore the potential neuroprotective properties of a pro-neurogenic compound NSI-189, Long-Evans rats were subjected to a clinically relevant fractionated irradiation protocol followed by four weeks of NSI-189 administered daily by oral gavage. Animals were then subjected to five different behavioral tasks followed by an analysis of neurogenesis, hippocampal volume and neuroinflammation. Irradiated cohorts manifested significant behavioral decrements on all four spontaneous exploration tasks. Importantly, NSI-189 treatment resulted in significantly improved performance in four of these tasks: novel place recognition, novel object recognition, object in place and temporal order. In addition, there was a trend of improved performance in the contextual phase of the fear conditioning task. Importantly, enhanced cognition in the NSI-189-treated cohort was found to persist one month after the cessation of drug treatment. These neurocognitive benefits of NSI-189 coincided with a significant increase in neurogenesis and a significant decrease in the numbers of activated microglia compared to the irradiated cohort that was given vehicle alone. The foregoing changes were not accompanied by major changes in hippocampal volume. These data demonstrate that oral administration of a pro-neurogenic compound exhibiting anti-inflammatory indications could impart long-term neurocognitive benefits in the irradiated brain.

Indexed as

Administration, OralAminopyridinesAnimalsCognitionCognitive DysfunctionConditioning, PsychologicalCranial IrradiationFearHippocampusNeuroprotective AgentsOrgan SizePiperazinesRadiation Injuries, ExperimentalRatsRecognition, PsychologyAminopyridinesNeuroprotective AgentsNSI-189Piperazines

Identifiers

PMID29351056
PMCPMC5910029
OpenAlexW2786837568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.